newsfilter
← Latest News
General Catalyst·

Accelerating Access to Medicine with Forus

Summary

  • One in three patients with high-cost or complex conditions never receive their first prescription dose, while others wait weeks or months due to insurance, affordability, and supply chain complexities.
  • Doctors often prescribe older, less effective therapies rather than cutting-edge treatments to avoid the administrative burden and potential patient disappointment associated with access barriers.
  • Forus utilizes Large Language Models to digest heterogeneous information and automate complex navigation, acting as an advocate layer that connects patients, providers, insurers, and manufacturers.
  • The platform serves patients in 80% of US zip codes, growing 10x in two years primarily through word of mouth, with tens of thousands of weekly users.
  • Forus provides free access to providers to build its network, which connects all transaction parties to eliminate friction without requiring individual stakeholders to navigate the complexity.
  • The company has reduced administrative complexity for providers by over 90% and accelerated medication delivery from weeks to one or two days.
  • Pharma & life sciences companies use Forus' network data to design better research, launch more efficiently, and align resources with actual patient access needs.
  • Founder Sahir Jaggi previously built health insurance at Oscar, which taught him the importance of high-caliber talent and the moral imperative to improve the healthcare operating system.
  • The business model prioritized network scale over early revenue, forgoing millions in short-term monetization to ensure durability and ubiquity.
  • Long-term goals include placing the platform in every US doctor's office and enabling life science companies to launch hundreds of drugs by making scientific discovery the only limit to patient access.

General Catalyst's Chris Bischoff sits down with Forus’s founder and CEO Sahir Jaggi to unpack why one in three patients never get their first dose of prescription medication, how LLMs cut through the complexity stalling the drug supply chain, and how a network built at scale can make scientific progress the only limit on the medicine that people have access to.